SunTrust analyst Gregg Gilbert lowered his price target on Allergan (AGN) to $170 after its Q1 results, modeling more conservative sales growth for its Botox from the entry of a new competitor Evolus (EOLS) into U.S. markets. The analyst also keeps his Buy rating on Allergan, stating that while he "shares" investors' frustration with its underperformance, he sees the valuation on the stock as reflective of its competitive threats and uninspiring pipeline. Gilbert anticipates an "attractive return" from Allergan over the next 12 months if the company can meet or exceed its financial targets or produce '"even mixed pipeline success."